Results of preclinical studies of PeFagTal®
A comparative study of the effect of the drug (in different doses) on three studied models of transplanted tumors relative to the comparison drug revealed significant differences in the relative area of tumor necrosis in individuals receiving the drug
(figure below).
(figure below).
About R&D
The current status of the project: based on the nanosomal delivery system created by BioTechnology LLC, the pharmaceutical development of the PeFagTal® for the treatment of breast cancer was carried out.
Preclinical trials of this drug acting on INTEGRIN avß3 for the treatmen of breast cancer have been conducted:
According to the results of the evaluation of the effect of inhibiting tumor growth, the degree of inhibition of tumor growth was calculated, which amounted to TPO≥90%, T/S ≤10%, which made it possible to evaluate the effectiveness of the antitumor effect of the drug as high*.
According to the results of the evaluation of the effect of inhibiting tumor growth, the degree of inhibition of tumor growth was calculated, which amounted to TPO≥90%, T/S ≤10%, which made it possible to evaluate the effectiveness of the antitumor effect of the drug as high*.
According to the State Standard 12.1.007-76, FS can be attributed to Class 3 - moderately toxic for mice,both with intragastric and intravenous routes of administration, and for rats - to the 2nd class of toxicity - highly toxic. According to the State Standard 12.1.007-76, GLF can be attributed to class 4 for rats – low-hazard substances. For rats with intragastric administration of GLF at the maximum possible dose, it is not possible to achieve LD50, since the dose of thallium nitrate is 1.08 mg / kg, which is 46 times less than LD50.
A preclinical study of the three-month "chronic" toxicity of FS and GLF of a drug acting on integrin avß3 for the treatment of breast cancer with intragastric use using a complex of biochemical, morphological, functional and general clinical research methods was carried out. When conducting experiments to study chronic toxicity, the safety of intragastric administration to rats of FS at doses of 1.54 mcg/ kg, 15.4 mcg/ kg, 154 mcg/kg and the safety of intragastric administration to rabbits of GLF at doses of 0.63 mcg/kg, 6.3 mcg/kg, 63 mcg/kg were proved.
The ability to exhibit allergenic properties has been revealed.No toxic effects were detected in relation to leukocyte, erythrocyte and platelet units of hematopoiesis, as well as indicators of the hemostasis system.
Histological examination of the tissues of the internal organs of animals revealed no signs of inflammatory, dystrophic, necrotic and other types of pathological processes.No local irritant effect was detected.
Histological examination of the tissues of the internal organs of animals revealed no signs of inflammatory, dystrophic, necrotic and other types of pathological processes.No local irritant effect was detected.
Our Contacts
Ask your question or you can call us
in a phone number below
in a phone number below
+998 90 902 20 01
projects@pefagtal.com
projects@pefagtal.com
Tashkent,Uzbekistan branch of BioTechnology
Kichik Beshagach st., 27, Tashkent, Uzbekistan
Representative in UAE
S M Management Consultancies Co.
Address: IBN BATUTA Gate Offices
Business Center, Office 57, 11th Floor,
PO Box 72800, Dubai, UAE
T: +971 50 154 65 71
Kichik Beshagach st., 27, Tashkent, Uzbekistan
Representative in UAE
S M Management Consultancies Co.
Address: IBN BATUTA Gate Offices
Business Center, Office 57, 11th Floor,
PO Box 72800, Dubai, UAE
T: +971 50 154 65 71